Paradigm Biocapital Advisors LP United Therapeutics Corp Transaction History

Paradigm Biocapital Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $14.6 Million - $17.1 Million	68,926 Added 28.91%	307,314 $69.4 Million
Q2 2023 Aug 14, 2023	BUY	$205.19 - $232.99 $5.44 Million - $6.17 Million	26,496 Added 12.5%	238,388 $52.6 Million
Q1 2023 May 15, 2023	BUY	$212.99 - $276.17 $13.4 Million - $17.4 Million	63,000 Added 42.31%	211,892 $47.5 Million
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $1.72 Million - $2.34 Million	8,331 Added 5.93%	148,892 $41.4 Million
Q3 2022 Nov 14, 2022	SELL	$203.3 - $244.17 $4.58 Million - $5.5 Million	-22,505 Reduced 13.8%	140,561 $29.4 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $15.3 Million - $21.1 Million	87,431 Added 115.6%	163,066 $38.4 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $12.6 Million - $16.2 Million	75,635 New	75,635 $13.6 Million

673

42.2M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.